AzurRx BioPharma Inc., a company specializing in the development of non-systemic, recombinant therapies for gastrointestinal diseases, has signed a binding letter of intent with Asymchem, a global contract development and manufacturing service (CDMO) provider, for the development and production of MS1819 for the treatment of exocrine pancreatic insufficiency.   Under the terms of the agreement, Asymchem will implement fermentation, verify protein expression and ultimately fine-tune the technolog...